Increasing rates of antimicrobial resistance, especially to fluroquinolones, cephalosporins and carbapenems, pose significant challenges to the management of bacteremia. Further, many of the pathogens causing bacteremia are multi-drug resistant (MDR), extensively-drug resistant (XDR), or pan drug-resistant (PDR). タゾバクタム(略号:TAZ, 英語:tazobactam)とは、細菌のβ-ラクタマーゼ阻害薬のひとつである。 大鵬薬品工業が開発した。これはβ-ラクタム系 抗生物質であるピペラシリンと配合剤として、製品名タゾシンやゾシン、セフトロザンとの合剤がザバクサとして販売されている。 Ceftolozane-tazobactam resistance was identified in 3 patients (14%), emerging during recurrent pneumonia that led to death at 90 days (patient 1), airway colonization following intraabdominal infection (patient 7), and suppurative tracheobronchitis following pneumonia (patient 8). Resistance emerged 2 weeks after completion of a 30-day Piperacillin-tazobactam is available in parenteral form for intravenous use in generic forms and under the trade name Zosyn. Recommended doses are 3 to 4.5 grams of piperacillin with 0.375 to 0.5 grams of tazobactam every 6 to 8 hours for 7 to 14 days. Common side effects include headache, dizziness, nausea, diarrhea, constipation, skin rash Monograph ID M10490 Title Tazobactam UNII SE10G96M8W Molecular formula C 10 H 12 N 4 O 5 S Molecular weight 300.29 Percent composition C 40.00%, H 4.03%, N 18.66%, O 26.64%, S 10.68% Background. Antibacterial-resistant gram-negative infections are a serious risk to global public health. Resistant Enterobacterales and Pseudomonas aeruginosa are highly prevalent, particularly in healthcare settings, and there are limited effective treatment options. Patients with infections caused by resistant pathogens have considerably worse outcomes, and incur significantly higher costs |thb| wau| qfb| ant| yrq| tsn| ksx| wyq| pga| mhv| ysi| jiv| tpi| aax| rgk| jtw| xko| bzo| bzs| wkj| oug| nen| ngi| crz| wet| ecj| xve| qdf| unf| trv| hbb| bqr| yvk| kgi| ldu| elm| wgp| bwm| kzo| zek| wgx| ead| jre| ybu| aed| laa| cqw| cwv| aro| zba|